Vyne Therapeutics Inc. (VYNE) — SEC Filings
Vyne Therapeutics Inc. (VYNE) — 25 SEC filings. Latest: S-4/A (Apr 28, 2026). Includes 11 8-K, 6 10-Q, 3 SC 13G/A.
View Vyne Therapeutics Inc. on SEC EDGAR
Overview
Vyne Therapeutics Inc. (VYNE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 17, 2025: VYNE Therapeutics Inc. filed an 8-K on December 17, 2025, reporting on several key events. These include entering into a material definitive agreement, unregistered sales of equity securities, and changes in control of the registrant. The filing also details the departure of directors or certain off
Sentiment Summary
Across 25 filings, the sentiment breakdown is: 3 bearish, 22 neutral. The dominant filing sentiment for Vyne Therapeutics Inc. is neutral.
Filing Type Overview
Vyne Therapeutics Inc. (VYNE) has filed 1 S-4/A, 11 8-K, 2 DEF 14A, 6 10-Q, 2 10-K, 3 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (25)
Risk Profile
Risk Assessment: Of VYNE's 19 recent filings, 3 were flagged as high-risk, 9 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $169K |
| Net Income | ($7.28M) |
| EPS | ($0.17) |
| Debt-to-Equity | 0.13 |
| Cash Position | $19.35M |
| Operating Margin | -4585.4% |
| Total Assets | $36.13M |
| Total Debt | $4.04M |
Key Executives
- David Domzalski
- Dr. Paul R. Edick
Industry Context
VYNE Therapeutics Inc. operates within the biotechnology and pharmaceutical sector, which is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. The industry is competitive, with companies focusing on innovation in specific therapeutic areas. Success often hinges on clinical trial outcomes, intellectual property protection, and successful commercialization strategies.
Top Tags
financials (5) · 10-Q (4) · Biotechnology (3) · financial-condition (3) · 8-K (3) · pharmaceutical (3) · executive-changes (2) · SEC Filing (2) · Clinical Trials (2) · Drug Development (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Shares Outstanding | 33,286,422 | Total common stock shares eligible to vote as of November 6, 2025 |
| Quorum Requirement | 11,095,474 | Minimum shares needed for the Annual Meeting to be valid (one-third of outstanding shares) |
| Proxy Solicitation Fee | $11,000 | Amount paid to D.F. King & Co., LLC for services |
| Annual Meeting Date | December 12, 2025 | Date of the Annual Meeting of Stockholders |
| Record Date | November 6, 2025 | Date by which stockholders must own shares to vote |
| Class I Directors | 2 | Number of directors to be elected to hold office until 2028 |
| Director Term Year | 2028 | Year until which elected Class I directors will hold office |
| Fiscal Year End | December 31, 2025 | Fiscal year for which Baker Tilly US, LLP is being ratified as auditor |
| Stockholder Proposal Deadline (Rule 14a-8) | July 15, 2026 | Deadline for submitting proposals for the 2026 annual meeting proxy statement |
| Stockholder Proposal Deadline (Bylaws - Earliest) | August 14, 2026 | Earliest date for submitting non-Rule 14a-8 proposals for the 2026 annual meeting |
| Net Loss (Q3 2025) | $7.28M | Decreased from $12.16M in Q3 2024 |
| Net Loss (9 Months 2025) | $21.65M | Decreased from $27.81M in 9 months 2024 |
| Royalty Revenues (Q3 2025) | $169K | Increased from $121K in Q3 2024 |
| Research and Development Expenses (Q3 2025) | $5.26M | Decreased from $10.25M in Q3 2024 |
| General and Administrative Expenses (Q3 2025) | $2.71M | Decreased from $2.96M in Q3 2024 |
Frequently Asked Questions
What are the latest SEC filings for Vyne Therapeutics Inc. (VYNE)?
Vyne Therapeutics Inc. has 25 recent SEC filings from Jan 2024 to Apr 2026, including 11 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VYNE filings?
Across 25 filings, the sentiment breakdown is: 3 bearish, 22 neutral. The dominant sentiment is neutral.
Where can I find Vyne Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vyne Therapeutics Inc. (VYNE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vyne Therapeutics Inc.?
Key financial highlights from Vyne Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VYNE?
The investment thesis for VYNE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vyne Therapeutics Inc.?
Key executives identified across Vyne Therapeutics Inc.'s filings include David Domzalski, Dr. Paul R. Edick.
What are the main risk factors for Vyne Therapeutics Inc. stock?
Of VYNE's 19 assessed filings, 3 were flagged high-risk, 9 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Vyne Therapeutics Inc.?
Forward guidance and predictions for Vyne Therapeutics Inc. are extracted from SEC filings as they are enriched.